HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Borghese Tightens Distribution To 500 Doors Under Management Redesign

This article was originally published in The Rose Sheet

Executive Summary

Borghese is trimming back distribution channels and reconfiguring its management design while stressing the company's position as the "ultimate Italian spa brand," CEO Georgette Mosbacher said.

You may also be interested in...



Borghese Romances Women With La Carezza d'Amore Launch

Borghese La Carezza d'Amore rich floral fragrance will debut in March as an expansion on the company's 1998 introduction, Gai Mattiolo. Combined, the two fragrances will mark the beginning of a series based on the theme of sensuality.

Borghese Romances Women With La Carezza d'Amore Launch

Borghese La Carezza d'Amore rich floral fragrance will debut in March as an expansion on the company's 1998 introduction, Gai Mattiolo. Combined, the two fragrances will mark the beginning of a series based on the theme of sensuality.

Borghese

Cura-C Vitamin C Eye Treatment, debuting in April, prevents the acceleration of premature aging by preserving, producing and repairing collagen, the firm says. The product joins the company's Cura-C Anhydrous Vitamin C Treatment (1"The Rose Sheet" Aug. 17, 1998, p. 3). With daily use of the eye cream, "dark circles, fine lines and signs of fatigue seem to disappear as elasticity is improved," Borghese claims. The product also contains borage seed oil and cyclomethicone to moisturize. A .5 oz. tube retails for $42.50

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel